Clinical Trial Update: A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase I/II trial evaluated vorinostat in combination with erlotinib for relapsed/refractory non-small cell lung cancer; results were posted in 2009…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2009-03-10